Testing baricitinib and sirolimus to control HIV after stopping treatment
Treatments studied
Part of Infections clinical trials.
This study tests two drugs, baricitinib and sirolimus, alone or together, to see if they can help control HIV after you stop your usual HIV medications for a short time. The goal is to see if these drugs can keep the virus from rebounding.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old (or up to 84 with doctor approval).
- You were diagnosed with HIV early (within about 2 months of infection) and started treatment soon after.
- You have been on HIV medications without stopping for at least 1 year, and your viral load has been undetectable for 6 months or more.
- Your CD4 count (immune cells) is 500 or higher.
- You are willing to stop your HIV medications for a period, as part of the study, and take an extra antiviral pill to prevent herpes.
- You do not have serious health conditions like heart disease, cancer, or active hepatitis B or C.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if two lab-made antibodies can keep HIV under control when people temporarily stop their daily HIV medication. Participants will pause their antiretroviral therapy (ART) for a period and be closely monitored, with the goal of potentially finding a way to take a break from daily pills.
This trial tests a new combination of three medications, lenacapavir, teropavimab, and zinlirvimab, for people with HIV who currently have undetectable virus levels on a stable oral treatment. The goal is to see if these drugs can keep the virus suppressed, possibly allowing a simpler treatment plan.
This study looks at people with HIV who have already taken a break from their HIV medications (called an analytic treatment interruption, or ATI) as part of another study. It aims to understand how well the body can control the virus during longer breaks from treatment, up to 96 weeks.
This study tests whether giving two experimental drugs together can help your immune system find and destroy hidden HIV cells. It aims to see if this approach can reduce the amount of virus in your body even while you're on your regular HIV medications.
This study tests a pill called baricitinib (already used for arthritis) to see if adding it to your HIV medications can help control the virus long-term. You might join if your HIV is well controlled and you are generally healthy.
This Phase 2 study tests baricitinib to see if it can lower HIV activity in the brain (CNS) for people already on stable HIV treatment. If you have well-controlled HIV in your blood, this trial looks for additional benefit inside the nervous system.
Hear when a new HIV-1-infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.